Form D · Other Health Care
D2 Pharma Consulting LLC
Chesterfield, MO · CIK 0001961414
Offering snapshot reported Jan 10, 2023 · SEC filing
- Reported sold
- $1.6M Offering amount: $3M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- Dec 28, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 10, 2023 | Initial | $1,600,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-470120
Source: Form D, filed Jan 10, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dean P Erhardt | Director, Executive |
| Steven Kirchof | Director |
| Richard Propper | Director |
| David Suchanek | Director |
| John Wagner | Director |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
400 Chesterfield Center Suite 400
Chesterfield, MO, 63017
Chesterfield, MO, 63017